Apocrine Neoplasm
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
Track Apocrine Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.